Last reviewed · How we verify

CCRF Consulting Co., Ltd. — Portfolio Competitive Intelligence Brief

CCRF Consulting Co., Ltd. pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Heparin or Bivalirudin Heparin or Bivalirudin marketed Anticoagulant Thrombin (Factor IIa) and Factor Xa (heparin); Thrombin (Factor IIa) (bivalirudin) Cardiovascular

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  2. Beijing Anzhen Hospital · 1 shared drug class
  3. Beijing Chao Yang Hospital · 1 shared drug class
  4. Beijing Suncadia Pharmaceuticals Co., Ltd · 1 shared drug class
  5. Boston Scientific Corporation · 1 shared drug class
  6. Deutsches Herzzentrum Muenchen · 1 shared drug class
  7. Faculty Hospital Kralovske Vinohrady · 1 shared drug class
  8. Anemia Working Group Romania · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for CCRF Consulting Co., Ltd.:

Cite this brief

Drug Landscape (2026). CCRF Consulting Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ccrf-consulting-co-ltd. Accessed 2026-05-17.

Related